Table 2.

Summary of partial FXR ligands entering clinical trials in liver disease.

Type	Ingredients	Study	Conditions	Status
Agonists	OCA	Phase 2 Study on Lipoprotein Metabolism	Primary Biliary Cirrhosis	Completed
Agonists	OCA	Evaluation of Pharmacokinetics and Safety	Liver Cirrhosis	Terminated
Agonists	Tropifexor (LJN452)	Safety and Tolerability.	Liver Disease	Completed
Agonists	Tropifexor (LJN452)	Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC	NASH and liver fibrosis	Completed
Agonists	Tropifexor (LJN452)	Evaluation of the Pharmacokinetics	NAFLD	Completed
Agonists	EYP001a	Food Effect Study in Subjects	Hepatitis B, Chronic	Completed
Agonists	EYP001a	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics	NASH	Completed
Agonists	ASC41	Evaluate the Safety, Tolerability, and Efficacy	NAFLD and NASH	Recruiting
Agonists	ASC41	Evaluate the Safety and Efficacy	Obesity and NAFLD	Completed
Agonists	EYP001a	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics	NASH	Completed
Agonists	EYP001a	Evaluation of the Safety and Pharmacology	Hepatitis B, Chronic	Completed
Agonists	Px-104	Safety Pilot Study	NAFLD	Completed
Agonists	TQA3526	Study in the Treatment	Primary Biliary Cirrhosis	Unknown
Agonists	MET409	Study to Evaluate Alone or Combination	NASH	Active, not recruiting
Agonists	TERN-501	Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics	NASH	Recruiting
Agonists	TERN-101	Safety, Tolerability, Efficacy, and Pharmacokinetics Study	NASH	Completed
Agonists	BAR502	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics	NAFLD	Not yet recruiting
Antagonist	Guggulsterone	Role in Hepatitis C Virus Replication	Chronic Hepatitis C	Terminated